These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 28823518)

  • 21. Prevention of thromboembolic complications in patients with superficial-vein thrombosis given rivaroxaban or fondaparinux: the open-label, randomised, non-inferiority SURPRISE phase 3b trial.
    Beyer-Westendorf J; Schellong SM; Gerlach H; Rabe E; Weitz JI; Jersemann K; Sahin K; Bauersachs R;
    Lancet Haematol; 2017 Mar; 4(3):e105-e113. PubMed ID: 28219692
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Retrospective comparison of low molecular weight heparin vs. warfarin vs. oral Xa inhibitors for the prevention of recurrent venous thromboembolism in oncology patients: The Re-CLOT study.
    Alzghari SK; Seago SE; Garza JE; Hashimie YF; Baty KA; Evans MF; Shaver C; Herrington JD
    J Oncol Pharm Pract; 2018 Oct; 24(7):494-500. PubMed ID: 28714376
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Risk factors of deep venous thrombosis associated with peripherally inserted central venous catheter in upper extremity in ICU].
    Zhao N; Zhang J; Jiang T; Chen X; Wang J; Ding C; Liu F; Qian K; Jiang R
    Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2017 Feb; 29(2):167-171. PubMed ID: 28625266
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rivaroxaban after Thrombolysis in Acute Iliofemoral Venous Thrombosis: A Randomized, Open-labeled, Multicenter Trial.
    Kang JM; Park KH; Ahn S; Cho S; Han A; Lee T; Jung IM; Kim JY; Min SK
    Sci Rep; 2019 Dec; 9(1):20356. PubMed ID: 31889152
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin K antagonists: a French nationwide propensity-matched cohort study.
    Maura G; Blotière PO; Bouillon K; Billionnet C; Ricordeau P; Alla F; Zureik M
    Circulation; 2015 Sep; 132(13):1252-60. PubMed ID: 26199338
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cerebral Venous Thrombosis at High Altitude: Analysis of 28 Cases.
    Hassan WU; Syed MJ; Alamgir W; Awan S; Bell SM; Majid A; Wasay M
    Cerebrovasc Dis; 2019; 48(3-6):184-192. PubMed ID: 31775151
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Resolution of acute lower extremity deep vein thrombosis with rivaroxaban compared to warfarin.
    Houghton DE; Lekah A; Macedo TA; Hodge D; Saadiq RA; Little Y; Casanegra AI; McBane RD; Wysokinski WE
    J Thromb Thrombolysis; 2020 Feb; 49(2):199-205. PubMed ID: 31422520
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Recurrence of malignancy-associated venous thromboembolism among patients treated with rivaroxaban compared to enoxaparin.
    Nicklaus MD; Ludwig SL; Kettle JK
    J Oncol Pharm Pract; 2018 Apr; 24(3):185-189. PubMed ID: 29284351
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rivaroxaban in the treatment of upper extremity deep vein thrombosis: A single-center experience and review of the literature.
    Schastlivtsev I; Lobastov K; Tsaplin S; Kanzafarova I; Barinov V; Laberko L; Rodoman G; Zhuravlev S
    Thromb Res; 2019 Sep; 181():24-28. PubMed ID: 31326717
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Risk factors for upper extremity venous thrombosis associated with peripherally inserted central venous catheters.
    Marnejon T; Angelo D; Abu Abdou A; Gemmel D
    J Vasc Access; 2012; 13(2):231-8. PubMed ID: 22266584
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomised controlled trials.
    Prins MH; Lensing AW; Brighton TA; Lyons RM; Rehm J; Trajanovic M; Davidson BL; Beyer-Westendorf J; Pap ÁF; Berkowitz SD; Cohen AT; Kovacs MJ; Wells PS; Prandoni P
    Lancet Haematol; 2014 Oct; 1(1):e37-46. PubMed ID: 27030066
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Upper extremity deep vein thrombosis associated with indwelling peripheral venous catheters in gynecology oncology patients.
    Schimp VL; Munkarah AR; Morris RT; Deppe G; Malone J
    Gynecol Oncol; 2003 May; 89(2):301-5. PubMed ID: 12713995
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparing Length of Stay Between Patients Taking Rivaroxaban and Conventional Anticoagulants for Treatment of Venous Thromboembolism.
    Desai A; Desai A; Calixte R; Aparnath M; Hindenburg A; Salzman S; Mathew JP
    Lung; 2016 Aug; 194(4):605-11. PubMed ID: 27192990
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Peripherally inserted central catheters and upper extremity deep vein thrombosis.
    Ong B; Gibbs H; Catchpole I; Hetherington R; Harper J
    Australas Radiol; 2006 Oct; 50(5):451-4. PubMed ID: 16981942
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of rivaroxaban mono-therapy and standard-therapy adjusted by CYP2C9 and VKORC1 genotypes in symptomatic pulmonary embolism.
    Duan L; Zhang N; Yan H; Guo Y; Hong C; Yang X; Su X; Chen R; Zhou Y; Zhong N; Liu C
    Clin Chim Acta; 2016 Aug; 459():25-29. PubMed ID: 27155586
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Successful use of rivaroxaban in postoperative deep vein thrombosis of the lower limb following instability with warfarin: a case report.
    Schiavoni M; Coluccia A
    J Med Case Rep; 2016 Oct; 10(1):276. PubMed ID: 27716428
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Risk factors associated with catheter-related upper extremity deep vein thrombosis in patients with peripherally inserted central venous catheters: a prospective observational cohort study: part 2.
    Maneval RE; Clemence BJ
    J Infus Nurs; 2014; 37(4):260-8. PubMed ID: 24983259
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A treatment strategy using subcutaneous fondaparinux followed by oral rivaroxaban is effective for treating acute venous thromboembolism.
    Kabuki T; Nakanishi R; Hisatake S; Fujii T; Dobashi S; Wakakura S; Kiuchi S; Fujino T; Ikeda T
    J Cardiol; 2017 Aug; 70(2):163-168. PubMed ID: 27979674
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Self-managed long-term low-molecular-weight heparin therapy: the balance of benefits and harms.
    Hull RD; Pineo GF; Brant RF; Mah AF; Burke N; Dear R; Wong T; Cook R; Solymoss S; Poon MC; Raskob G;
    Am J Med; 2007 Jan; 120(1):72-82. PubMed ID: 17208082
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Initiation of rivaroxaban in patients with nonvalvular atrial fibrillation at the primary care level: the Swiss Therapy in Atrial Fibrillation for the Regulation of Coagulation (STAR) Study.
    Engelberger RP; Noll G; Schmidt D; Alatri A; Frei B; Kaiser WE; Kucher N
    Eur J Intern Med; 2015 Sep; 26(7):508-14. PubMed ID: 25935131
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.